A recent study analyzed Medicare claims data from 2013 to 2020 in older adults with HIV and atrial fibrillation who initiated oral anticoagulants. The study found that apixaban may present a safer anticoagulation option compared to warfarin and rivaroxaban in this high-risk patient population, with significantly lower risks of major bleeding. No significant differences in ischemic stroke or all-cause mortality rates were observed, but gastrointestinal bleeding risks were higher for warfarin and rivaroxaban. The study also highlighted the potential drug interactions between antiretroviral therapy and oral anticoagulants, warranting further investigation.

Source: JAMA Internal Medicine